AAV8 Gene Therapy for Crigler-Najjar Syndrome in Macaques Elicited Transgene T Cell Responses That Are Resident to the Liver.

Abstract:

:Systemic delivery of adeno-associated viral (AAV) vectors has been evaluated for the treatment of several liver diseases, including homozygous familial hypercholesterolemia, ornithine transcarbamylase deficiency, and hemophilia. Here, we evaluated this approach for the treatment of Crigler-Najjar syndrome. We administered wild-type rhesus macaques with 1.0 × 1013 or 2.5 × 1013 genome copies/kg of an AAV serotype 8 vector expressing a codon-optimized version of human uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) from a liver-specific promoter. We extensively studied vector biodistribution, transgene expression, and immune responses following vector administration. All rhesus macaques survived until their scheduled necropsy at day 56 and showed no clinical abnormalities during the course of the study. Macaques administered with either vector dose developed a T cell response to the AAV capsid and/or transgene. We mapped the immunodominant epitope in the human UGT1A1 sequence, and we found no correlation between peripheral and tissue-resident lymphocyte responses. Upon further investigation, we characterized CD107a+, granzyme B+, CD4+, and CD8+ transgene-specific cellular responses that were restricted to tissue-resident T cells. This study highlights the importance of studying immune responses at the vector transduction site and the limited usefulness of blood as a surrogate to evaluate tissue-restricted T cell responses.

authors

Greig JA,Calcedo R,Kuri-Cervantes L,Nordin JML,Albrecht J,Bote E,Goode T,Chroscinski EA,Bell P,Richman LK,Betts MR,Wilson JM

doi

10.1016/j.omtm.2018.10.012

subject

Has Abstract

pub_date

2018-12-05 00:00:00

pages

191-201

issn

2329-0501

pii

S2329-0501(18)30108-6

journal_volume

11

pub_type

杂志文章
  • Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.

    abstract::The marketing approval of genetically engineered hematopoietic stem cells (HSCs) as the first-line therapy for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is a tribute to the substantial progress that has been made regarding HSC engineering in the past decade. Rep...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章,评审

    doi:10.1016/j.omtm.2017.03.003

    authors: Wang X,Rivière I

    更新日期:2017-03-18 00:00:00

  • Cre Recombinase Mediates the Removal of Bacterial Backbone to Efficiently Generate rSV40.

    abstract::Gene therapy has been shown to be a feasible approach to treat inherited disorders in vivo. Among the currently used viral vector systems, adeno-associated virus (AAV) vectors are the most advanced and have been applied in patients successfully. An important drawback of non-integrating AAV vectors is their loss of exp...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.02.010

    authors: Shi X,Ykema MR,Hazenoot J,Ten Bloemendaal L,Mancini I,Odijk M,de Haan P,Bosma PJ

    更新日期:2018-02-27 00:00:00

  • Human Umbilical Tissue-Derived Cells Secrete Soluble VEGFR1 and Inhibit Choroidal Neovascularization.

    abstract::Exudative age-related macular degeneration (AMD), characterized by choroidal neovascularization (CNV), is the leading cause of irreversible blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs are the standard treatment for AMD, but they have limitations. Cell therapy is a promising a...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.05.007

    authors: Cao J,Yang R,Smith TE,Evans S,McCollum GW,Pomerantz SC,Petley T,Harris IR,Penn JS

    更新日期:2019-05-22 00:00:00

  • Plastin 3 Promotes Motor Neuron Axonal Growth and Extends Survival in a Mouse Model of Spinal Muscular Atrophy.

    abstract::Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease. SMA is caused by mutations in the survival motor neuron gene (SMN1), leading to reduced levels of SMN protein in the CNS. The actin-binding protein plastin 3 (PLS3) has been reported as a modifier for SMA, making it a potential therapeutic ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.01.007

    authors: Alrafiah A,Karyka E,Coldicott I,Iremonger K,Lewis KE,Ning K,Azzouz M

    更新日期:2018-01-31 00:00:00

  • Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors.

    abstract::Adeno-associated virus (AAV) vectors have emerged as a safe and efficient gene therapy platform. One complication is that a significant amount of empty particles have always been generated as impurities during AAV vector production. However, the effects of such particles on AAV vector performance remain unclear. Here ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2016.12.004

    authors: Wang Q,Dong B,Pokiniewski KA,Firrman J,Wu Z,Chin MP,Chen X,Liu L,Xu R,Diao Y,Xiao W

    更新日期:2016-12-24 00:00:00

  • Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene.

    abstract::In vivo imaging of vector transgene expression would be particularly valuable for repetitive monitoring of therapy in the brain, where invasive tissue sampling is contraindicated. We evaluated adeno-associated virus vector expression of a dopamine-2 receptor (D2R) mutant (D2R80A) by positron emission tomography in the...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2014.16

    authors: Yoon SY,Gay-Antaki C,Ponde DE,Poptani H,Vite CH,Wolfe JH

    更新日期:2014-06-04 00:00:00

  • A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI.

    abstract::Identification and characterization of disease-associated variants in monogenic disorders is an important aspect of diagnosis, genetic counseling, prediction of disease severity, and development of therapy. However, the effects of disease-associated variants on pre-mRNA splicing and mRNA degradation are difficult to p...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.09.004

    authors: Broeders M,Smits K,Goynuk B,Oussoren E,van den Hout HJMP,Bergsma AJ,van der Ploeg AT,Pijnappel WWMP

    更新日期:2020-09-16 00:00:00

  • A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications.

    abstract::Surfactant protein B (SPB) deficiency is a severe monogenic interstitial lung disorder that leads to loss of life in infants as a result of alveolar collapse and respiratory distress syndrome. The development and assessment of curative therapies for the deficiency are limited by the general lack of well-characterized ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.11.013

    authors: Munis AM,Hyde SC,Gill DR

    更新日期:2020-11-20 00:00:00

  • Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice.

    abstract::New methods to produce large numbers of myeloid progenitor cells, precursors to macrophages (MΦs), by maintaining Hoxb8 transcription factor activity1 has reinvigorated interest in MΦ cell therapies. We generated Hoxb8-dependent myeloid progenitors (HDPs) by transducing lineage-negative bone marrow cells with a consti...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2017.08.007

    authors: Lee S,Kivimäe S,Szoka FC

    更新日期:2017-09-07 00:00:00

  • Genetically Corrected iPSC-Derived Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect CNS Disease in Sanfilippo B Mice.

    abstract::Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB [MPS IIIB]) is a lysosomal storage disorder primarily affecting the brain that is caused by a deficiency in the enzyme α-N-acetylglucosaminidase (NAGLU), leading to intralysosomal accumulation of heparan sulfate. There are currently no treatments for this dis...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.06.005

    authors: Clarke D,Pearse Y,Kan SH,Le SQ,Sanghez V,Cooper JD,Dickson PI,Iacovino M

    更新日期:2018-07-23 00:00:00

  • Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration.

    abstract::Preclinical studies have demonstrated that a single injection of an adeno-associated virus (AAV) vector into the cerebrospinal fluid (CSF) can achieve widespread gene transfer throughout the central nervous system. Successfully translating this approach to humans requires identifying factors that influence AAV distrib...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.04.012

    authors: Hinderer C,Katz N,Dyer C,Goode T,Johansson J,Bell P,Richman L,Buza E,Wilson JM

    更新日期:2020-04-18 00:00:00

  • Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing.

    abstract::The advent of RNA-guided endonuclease (RGEN)-mediated gene editing, specifically via CRISPR/Cas9, has spurred intensive efforts to improve the efficiency of both RGEN delivery and targeted mutagenesis. The major viral vectors in use for delivery of Cas9 and its associated guide RNA, lentiviral and adeno-associated vir...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.57

    authors: Park A,Hong P,Won ST,Thibault PA,Vigant F,Oguntuyo KY,Taft JD,Lee B

    更新日期:2016-08-24 00:00:00

  • Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency.

    abstract::X-linked severe combined immunodeficiency (SCID-X1) is caused by mutations in the interleukin-2 receptor γ chain gene (IL2RG), and it is characterized by profound defects in T, B, and natural killer (NK) cell functions. Transplantation of hematopoietic stem/progenitor cells (HSPCs) genetically corrected with early mur...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.03.002

    authors: Poletti V,Charrier S,Corre G,Gjata B,Vignaud A,Zhang F,Rothe M,Schambach A,Gaspar HB,Thrasher AJ,Mavilio F

    更新日期:2018-03-10 00:00:00

  • Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes.

    abstract::Osteoarthritis (OA) is a joint disease characterized by degeneration of the articular cartilage, subchondral bone remodeling, and secondary inflammation. It is among the top three causes of chronic disability, and currently there are no treatment options to prevent disease progression. The localized nature of OA makes...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.8

    authors: Ruan MZ,Cerullo V,Cela R,Clarke C,Lundgren-Akerlund E,Barry MA,Lee BH

    更新日期:2016-03-09 00:00:00

  • Transduction Pattern of AAVs in the Trabecular Meshwork and Anterior-Segment Structures in a Rat Model of Ocular Hypertension.

    abstract::Adeno-associated viruses (AAVs) are the vector of choice for gene therapy in the eye, and self-complementary AAVs (scAAVs), which do not require second-strand DNA synthesis, can be transduced into cells of the trabecular meshwork (TM). The scAAV transduction patterns in the anterior segment of normotensive eyes have b...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.06.009

    authors: Lee SH,Sim KS,Kim CY,Park TK

    更新日期:2019-07-10 00:00:00

  • Membrane-stabilizing copolymers confer marked protection to dystrophic skeletal muscle in vivo.

    abstract::Duchenne muscular dystrophy (DMD) is a fatal disease of striated muscle deterioration. A unique therapeutic approach for DMD is the use of synthetic membrane stabilizers to protect the fragile dystrophic sarcolemma against contraction-induced mechanical stress. Block copolymer-based membrane stabilizer poloxamer 188 (...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2015.42

    authors: Houang EM,Haman KJ,Filareto A,Perlingeiro RC,Bates FS,Lowe DA,Metzger JM

    更新日期:2015-11-11 00:00:00

  • TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle.

    abstract::Pompe disease (PD) is a lysosomal disorder caused by acid α-glucosidase (GAA) deficiency. Progressive muscular weakness is the major symptom of PD, and enzyme replacement therapy can improve the clinical outcome. However, to achieve a better clinical outcome, alternative therapeutic strategies are being investigated, ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.54

    authors: Sato Y,Kobayashi H,Higuchi T,Shimada Y,Ida H,Ohashi T

    更新日期:2016-08-10 00:00:00

  • Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome.

    abstract::Liver metabolism disorders are attractive targets for gene therapy, because low vector doses can reverse the buildup of toxic metabolites in the blood. Crigler-Najjar syndrome is an inherited disorder of bilirubin metabolism that is caused by the absence of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) act...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.07.008

    authors: Greig JA,Nordin JML,Draper C,McMenamin D,Chroscinski EA,Bell P,Gray JT,Richman LK,Wilson JM

    更新日期:2018-07-21 00:00:00

  • Human fetal liver cells for regulated ex vivo erythropoietin gene therapy.

    abstract::Possible risks and lack of donor livers limit application of liver transplantation. Liver cell transplantation is, at this moment, not a feasible alternative because engraftment in the liver is poor. Furthermore, there is also shortage of cells suitable for transplantation. Fetal liver cells are able to proliferate in...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2014.3

    authors: El Filali E,Duijst S,Hiralall JK,Legrand N,van Gulik T,Hoekstra R,Seppen J

    更新日期:2014-03-12 00:00:00

  • Simple and Fast SEC-Based Protocol to Isolate Human Plasma-Derived Extracellular Vesicles for Transcriptional Research.

    abstract::Extracellular vesicles (EVs) are membranous structures that protect RNAs from damage when circulating in complex biological fluids, such as plasma. RNAs are extremely specific to health and disease, being powerful tools for diagnosis, treatment response monitoring, and development of new therapeutic strategies for sev...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.07.012

    authors: Gaspar LS,Santana MM,Henriques C,Pinto MM,Ribeiro-Rodrigues TM,Girão H,Nobre RJ,Pereira de Almeida L

    更新日期:2020-07-15 00:00:00

  • ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles.

    abstract::Pancreatic cancer is an aggressive malignancy that often goes undiagnosed in the early stages. Non-invasive, early, and accurate diagnosis is therefore undoubtedly the "holy grail" of pancreatic cancer research. However, despite extensive research efforts, there is no definitive biomarker for this cancer. Previously, ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.08.016

    authors: Shin HS,Jung SB,Park S,Dua P,Lee DK

    更新日期:2019-09-12 00:00:00

  • Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A.

    abstract::The delivery of factor VIII (FVIII) through gene and/or cellular platforms has emerged as a promising hemophilia A treatment. Herein, we investigated the suitability of human placental cells (PLCs) as delivery vehicles for FVIII and determined an optimal FVIII transgene to produce/secrete therapeutic FVIII levels from...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.03.001

    authors: El-Akabawy N,Rodriguez M,Ramamurthy R,Rabah A,Trevisan B,Morsi A,George S,Shields J,Meares D,Farland A,Atala A,Doering CB,Spencer HT,Porada CD,Almeida-Porada G

    更新日期:2020-03-14 00:00:00

  • piggyBac-mediated phenotypic correction of factor VIII deficiency.

    abstract::Hemophilia A, caused by a deficiency in factor VIII (FVIII), is the most severe inherited bleeding disorder. Hemophilia A is an attractive gene therapy candidate because even small increases in FVIII levels will positively alter the phenotype. While several vectors are under investigation, gene addition from an integr...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2014.42

    authors: Staber JM,Pollpeter MJ,Arensdorf A,Sinn PL,Rutkowski DT,McCray PB Jr

    更新日期:2014-09-10 00:00:00

  • A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence.

    abstract::Recombinant adeno-associated virus (rAAV) is currently the best vector for gene delivery into the skeletal muscle. However, the 5-kb packaging size of this virus is a major obstacle for large gene transfer. This past decade, many different strategies were developed to circumvent this issue (concatemerization-splicing,...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2015.9

    authors: Pryadkina M,Lostal W,Bourg N,Charton K,Roudaut C,Hirsch ML,Richard I

    更新日期:2015-03-25 00:00:00

  • RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope.

    abstract::To date, gene therapy with transiently derived lentivectors has been very successful to cure rare infant genetic diseases. However, transient manufacturing is unfeasible to treat adult malignancies because large vector lots are required. By contrast, stable manufacturing is the best option for high-incidence diseases ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.33

    authors: Marin V,Stornaiuolo A,Piovan C,Corna S,Bossi S,Pema M,Giuliani E,Scavullo C,Zucchelli E,Bordignon C,Rizzardi GP,Bovolenta C

    更新日期:2016-05-11 00:00:00

  • Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies.

    abstract::Because many peptide and peptide-mimetic drugs are substrates of peptide transporter 1, it is important to evaluate the peptide transporter 1-mediated intestinal absorption of drug candidates in the early phase of drug development. Although intestinal cell lines treated with inhibitors of peptide transporter 1 are wid...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.11.008

    authors: Kawai K,Negoro R,Ichikawa M,Yamashita T,Deguchi S,Harada K,Hirata K,Takayama K,Mizuguchi H

    更新日期:2019-11-21 00:00:00

  • A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors.

    abstract::Recombinant adeno-associated viral (rAAV) vectors have been widely used in human gene therapy. One major impediment to its broad application is the inability to produce high-quality vectors in mass quantity. Here, an efficient and scalable suspension cell culture system for the production of rAAV vectors is described....

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2017.11.002

    authors: Wang Q,Wu Z,Zhang J,Firrman J,Wei H,Zhuang Z,Liu L,Miao L,Hu Y,Li D,Diao Y,Xiao W

    更新日期:2017-11-07 00:00:00

  • Development of Gene Transfer for Induction of Antigen-specific Tolerance.

    abstract::Gene replacement therapies, like organ and cell transplantation are likely to introduce neo-antigens that elicit rejection via humoral and/or effector T cell immune responses. Nonetheless, thanks to an ever growing body of pre-clinical studies it is now well accepted that gene transfer protocols can be specifically de...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2014.13

    authors: Sack BK,Herzog RW,Terhorst C,Markusic DM

    更新日期:2014-04-30 00:00:00

  • Development of a real-time imaging system for hypoxic cell apoptosis.

    abstract::Hypoxic regions within the tumor form due to imbalances between cell proliferation and angiogenesis; specifically, temporary closure or a reduced flow due to abnormal vasculature. They create environments where cancer cells acquire resistance to therapies. Therefore, the development of therapeutic approaches targeting...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.9

    authors: Kagiya G,Ogawa R,Hyodo F,Yamashita K,Nakamura M,Ishii A,Sejimo Y,Tominaga S,Murata M,Tanaka Y,Hatashita M

    更新日期:2016-03-02 00:00:00

  • A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome.

    abstract::Crigler-Najjar syndrome is a severe metabolic disease of the liver due to a reduced activity of the UDP Glucuronosyltransferase 1A1 (UGT1A1) enzyme. In an effort to translate to the clinic an adeno-associated virus vector mediated liver gene transfer approach to treat Crigler-Najjar syndrome, we developed and optimize...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.49

    authors: Ronzitti G,Bortolussi G,van Dijk R,Collaud F,Charles S,Leborgne C,Vidal P,Martin S,Gjata B,Sola MS,van Wittenberghe L,Vignaud A,Veron P,Bosma PJ,Muro AF,Mingozzi F

    更新日期:2016-07-20 00:00:00